Psoriatic arthritis treatment: biological response modifiers - Wikidata - awgldk - TriplyDB

Psoriatic arthritis treatment: biological response modifiers

Psoriatic arthritis treatment: biological response modifiers

http://www.wikidata.org/entity/Q36040084

about

Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.Psoriatic arthritis assessment tools in clinical trials.Psoriatic arthritis and imaging.Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?Measuring disease activity in psoriatic arthritis.TNFalpha blockade in human diseases: an overview of efficacy and safety.Infliximab (Remicade) in the treatment of psoriatic arthritis.Biologics in dermatology.Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Adalimumab in the treatment of arthritis Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.

P2860

Q26862017-953FE4C9-7C31-4EB2-B3EC-2CF9358E9FBD Q34027596-542D66DA-7EA9-422B-8160-478F44F25835 Q35579450-81804728-165D-4949-99A7-1EDC08637AE0 Q35579462-D260E892-61D2-4CE2-8426-2073F900DB83 Q36040064-E1BDD26A-C357-471E-870A-636A7D7341A1 Q36404862-2769E7A0-77DA-411C-8ECF-979B407611E2 Q36520126-607D5423-E016-41B2-8F2E-7757343A42CF Q36536861-C6B3E417-0F7C-4B99-AEB4-13C211361762 Q37116853-431C7B63-893F-413A-A949-2A657391BC96 Q37277398-897AD484-8483-41BE-B8CD-0564F26F93D5 Q37453027-681188AA-446A-4010-B2EE-A5E741F6F554 Q42009131-FD489800-3344-4F65-B930-FB9C1ED4EA95 Q43554532-70C60289-3F49-402A-893B-CD7A5AF394E3

P2860

Psoriatic arthritis treatment: biological response modifiers

http://www.wikidata.org/entity/Q36040084

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Psoriatic arthritis treatment: biological response modifiers

@ast

Psoriatic arthritis treatment: biological response modifiers

@en

type

label

Psoriatic arthritis treatment: biological response modifiers

@ast

Psoriatic arthritis treatment: biological response modifiers

@en

prefLabel

Psoriatic arthritis treatment: biological response modifiers

@ast

Psoriatic arthritis treatment: biological response modifiers

@en

P1433

Q36040084-A5FA2040-AB16-4E77-BB67-A2DF0E8EA0CC

P1476

Q36040084-7B2831E0-349B-4C90-AA8C-D222547F7EB0

P2093

Q36040084-05C08017-B297-4952-BDB9-2382FB3A9D04

Q36040084-4D29C07E-7988-4D22-8960-CCABE1120BAF

P2860

Q36040084-0E8934A7-17D5-4CBE-8D25-0D66249462B2

Q36040084-15318B1E-3055-4EB0-91E5-DDAF8548A753

Q36040084-172A3671-9FE3-465B-9F64-8F3B046B38A9

Q36040084-1C91AC4D-7655-42CD-A042-DB458534D092

Q36040084-2C1EBCFF-501D-42F1-873B-B5B03176BE0F

Q36040084-2CDE63A6-0C65-43E3-98C1-7D92F718F2B6

Q36040084-3B12C3EE-E9E1-4E72-8313-925E2D842D89

Q36040084-3C0875B7-C4C8-4300-91AC-01681AEECEA4

Q36040084-43A43D64-53CF-423B-97DF-F8F75D18439F

Q36040084-4B143957-8CD5-4D59-B433-0C5490AC7DB3

P304

Q36040084-E79BB351-86DB-48AC-B423-EF82EFE2E9D8

P31

Q36040084-8E44C4CE-4853-4EB9-853D-B729574CC711

P356

Q36040084-2E7319FA-D69E-44AE-9B79-383A754C12E4

P407

Q36040084-A3CE874C-8385-4CEC-8038-70883C08B916

P478

Q36040084-7F7BC24B-1127-49CF-937F-077B20F2F5A5

P577

Q36040084-C5A8F8B7-EA0F-4C0C-B873-820D93DD16D0

P5875

Q36040084-AC51510C-6FB8-4A11-B1F1-FAEA4757BA1C

P698

Q36040084-6BD9A97B-4819-400D-A8D4-10F20DB637F5

P932

Q36040084-238385AD-E034-409C-AC66-FB0A4402CD00

P356

ARD.2004.034157

P1433

Annals of the Rheumatic Diseases

P1476

Psoriatic arthritis treatment: biological response modifiers

@en

P2093

Antoni CE

http://www.w3.org/2001/XMLSchema#string

Mease PJ

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Immunology of tuberculosis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Onercept. Serono.

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

P304

ii78-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2004.034157

http://www.w3.org/2001/XMLSchema#string

P407

P478

64 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8024061

http://www.w3.org/2001/XMLSchema#string

P698

15708944

http://www.w3.org/2001/XMLSchema#string

P932

1766864

http://www.w3.org/2001/XMLSchema#string